title: A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta.
abstract: Bone mineral density and fracture rates in children with osteogenesis imperfecta improve with intravenous bisphosphonates. The efficacy of oral bisphosphonates has not been established. This report is an analysis of an open-label, prospective, randomized clinical trial of oral compared to intravenous bisphosphonate medications in children with osteogenesis imperfecta. Children were stratified according to bone age, pubertal stage, and type of osteogenesis imperfecta and then randomized to receive intravenous pamidronate, 3 mg/kg over 3 days every 4 months, or oral alendronate 1 mg/kg, from a minimum of 10 mg to a maximum of 20 mg daily. The primary efficacy outcome was change in bone mineral density. Secondary outcomes included change in biomarkers of bone turnover, fracture incidence, and growth rate. Ten children were randomized (6 oral and 4 intravenous). Two other children were assigned to intravenous treatment due to chronic abdominal pain. In each group, three patients had type III/IV osteogenesis imperfecta, while three had type I. All 12 children completed 8 months of therapy; nine completed 12 months. Bone mineral density increased in both oral and intravenous groups equally and beyond that expected with normal growth. All children had a decrease in biochemical markers of bone turnover. Linear growth showed a moderate increase above that for age. There was a non-significant decrease in fracture incidence in both groups.
authors.affiliation: Department of Pediatrics, Section of Pediatric Endocrinology & Diabetology, Indiana University School of Medicine, Indianapolis, IN, USA. dimeglio@iupui.edu
authors.forename: L A
authors.initials: LA
authors.lastname: Dimeglio
authors.forename: L
authors.initials: L
authors.lastname: Ford
authors.forename: C
authors.initials: C
authors.lastname: McClintock
authors.forename: M
authors.initials: M
authors.lastname: Peacock
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000367:Age Factors; D019386:Alendronate / Q000008:administration & dosage* / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000627:therapeutic use*; D015519:Bone Density; D002648:Child; D002657:Child Development; D002675:Child, Preschool; D004164:Diphosphonates / Q000008:administration & dosage* / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D010013:Osteogenesis Imperfecta / Q000188:drug therapy* / Q000473:pathology; D000077268:Pamidronate; D011446:Prospective Studies; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D004164:Diphosphonates; D000077268:Pamidronate; D019386:Alendronate